Association of Employment Status With Symptom Burden and Health-Related Quality of Life in People Living With Primary CNS Tumors

Background and Objectives Financial toxicity significantly affects many patients, especially cancer survivors. We evaluated the association of unemployment as a major contributor to financial toxicity with patient-reported outcomes (PROs) assessing multiple illness experience domains in a primary CNS tumor (PCNST) cohort. Methods Patient and disease characteristics and PROs measuring symptom burden, interference, psychologic distress, functional impairment, and health-related quality of life (HRQOL) from participants enrolled in an institutional review board–approved observational study at the US NIH's Neuro-Oncology Branch were collected between September 2016 and December 2019. Descriptive statistics, tests of association, and comparison of group mean values were used to describe and evaluate PROs. Results Of the 277 participants diagnosed with a PCNST, 57% were male and 43% were female. Participants reported their race as White, non-Hispanic (78%); White, Hispanic/Latino (9%); Asian (7%); Black (4%); Native Hawaiian/Pacific Islander (1%); and other (2%) with 8% missing. The median age of the overall cohort was 45 years (range 18–74). Hispanic participants in the overall sample were 2.3 times more likely, and in the brain tumor group 3.2 times more likely, to report unemployment (p = 0.043, odds ratio [OR] 2.3, 95% CI 1.0–5.4 and p = 0.008, OR 3.2, 95% CI 1.3–7.9, respectively). 77 (28%) individuals unemployed due to tumor reported more functional impairment with walking, washing, dressing, and performing usual activities and reduced HRQOL (p < 0.001). More unemployed participants in the total sample reported moderate-to-severe depressive symptoms (25%) than those employed (8%) (χ2(1) = 13.9, p < 0.001, OR 3.7, 95% CI 1.8–7.8) and more moderate-to-severe anxiety symptoms (30%) than those employed (15%) (χ2(1) = 7.8, p = 0.005, OR 2.4, 95% CI 1.3–4.5). Unemployed participants with brain tumor reported on average 3 more symptoms as moderate-to-severe compared with those employed (t(83) = −4.0, 95% CI difference −5 to −2, p < 0.001, Hedge g = 0.70). Discussion Being unemployed due to a PCNST strongly correlated with high symptom burden, functional impairment, psychological distress, and reduced HRQOL, which may be impediments to returning to work that warrant intervention. Lack of employer-based health insurance and reduced earnings are financial sequelae of unemployment superimposed on the physical, social, and cognitive effects of living with a PCNST. Innovations to screen for and address financial toxicity and its contributing factors are needed.

[1]  A. Jemal,et al.  Annual Report to the Nation on the Status of Cancer, Part 2: Patient Economic Burden Associated With Cancer Care , 2021, Journal of the National Cancer Institute.

[2]  B. Reeve,et al.  Systematic review of financial burden assessment in cancer: Evaluation of measures and utility among adolescents and young adults and caregivers , 2021, Cancer.

[3]  S. Kalkanis,et al.  The economic impact of glioma survivorship , 2020, Neurology.

[4]  J. Reijneveld,et al.  Healthcare utilization and productivity loss in glioma patients and family caregivers: the impact of treatable psychological symptoms , 2020, Journal of Neuro-Oncology.

[5]  Center for Devices and Radiological Health , 2020, Definitions.

[6]  B. Gyawali,et al.  Financial toxicity of cancer treatment: Moving the discussion from acknowledgement of the problem to identifying solutions , 2020, EClinicalMedicine.

[7]  F. Gany,et al.  Impact of Cancer on Employment. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Jacobsen,et al.  Developing a Quality of Cancer Survivorship Care Framework: Implications for Clinical Care, Research and Policy. , 2019, Journal of the National Cancer Institute.

[9]  T. Ownsworth,et al.  Subjective cognitive functioning and associations with psychological distress in adult brain tumour survivors , 2019, Journal of Cancer Survivorship.

[10]  J. Wiskemann,et al.  Return to work after breast cancer: The role of treatment-related side effects and potential impact on quality of life. , 2019, European journal of cancer care.

[11]  Zhiyuan Zheng,et al.  The social and economic toll of cancer survivorship: a complex web of financial sacrifice , 2019, Journal of Cancer Survivorship.

[12]  J. Lindström,et al.  Chronic Diseases and Employment: Which Interventions Support the Maintenance of Work and Return to Work among Workers with Chronic Illnesses? A Systematic Review , 2019, International journal of environmental research and public health.

[13]  E. Adjei Boakye,et al.  Comparison of the Financial Burden of Survivors of Head and Neck Cancer With Other Cancer Survivors , 2019, JAMA otolaryngology-- head & neck surgery.

[14]  H. Kantarjian,et al.  The financial burden and distress of patients with cancer: Understanding and stepping‐up action on the financial toxicity of cancer treatment , 2018, CA: a cancer journal for clinicians.

[15]  C. Alfano,et al.  Making Cancer Rehabilitation Services Work for Cancer Patients: Recommendations for Research and Practice to Improve Employment Outcomes , 2017, PM & R : the journal of injury, function, and rehabilitation.

[16]  M. Clark,et al.  Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer. , 2017, Clinical lung cancer.

[17]  M. Frings-Dresen,et al.  Return to work of cancer patients after a multidisciplinary intervention including occupational counselling and physical exercise in cancer patients: a prospective study in the Netherlands , 2017, BMJ Open.

[18]  F. Gany,et al.  Women With Breast Cancer Who Work For Accommodating Employers More Likely To Retain Jobs After Treatment. , 2017, Health affairs.

[19]  R. Yabroff,et al.  Financial Hardships Experienced by Cancer Survivors: A Systematic Review , 2017, Journal of the National Cancer Institute.

[20]  L. Deangelis,et al.  Anaplastic astrocytoma and non-1p/19q co-deleted anaplastic oligoastrocytoma: long-term survival, employment, and performance status of survivors. , 2016, Neuro-oncology practice.

[21]  M. Frings-Dresen,et al.  Effective return-to-work interventions after acquired brain injury: A systematic review , 2016, Brain injury.

[22]  C. Amidei,et al.  Rehabilitation of motor dysfunction in primary brain tumor patients†. , 2015, Neuro-oncology practice.

[23]  M. Gilbert,et al.  The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. , 2014, Neuro-oncology.

[24]  J. Griggs,et al.  Impact of adjuvant chemotherapy on long‐term employment of survivors of early‐stage breast cancer , 2014, Cancer.

[25]  Zhiyuan Zheng,et al.  Medical Costs and Productivity Losses of Cancer Survivors — United States, 2008–2011 , 2014, MMWR. Morbidity and mortality weekly report.

[26]  A. Rademaker,et al.  Financial burden experienced by patients undergoing treatment for malignant gliomas. , 2014, Neuro-oncology practice.

[27]  P. Wilford,et al.  Predicting outcomes of vocational rehabilitation in patients with brain tumours , 2013, Psycho-oncology.

[28]  D. Ekwueme,et al.  Economic burden of cancer survivorship among adults in the United States. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  C. Gudex,et al.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study , 2012, Quality of Life Research.

[30]  Amardeep Thind,et al.  Return to work in low‐income Latina and non‐Latina white breast cancer survivors: A 3‐year longitudinal study , 2012, Cancer.

[31]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[32]  J. Olesen,et al.  The economic cost of brain disorders in Europe , 2012, European journal of neurology.

[33]  S. Reise,et al.  Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger , 2011, Assessment.

[34]  M. Gilbert,et al.  Reliability and validity of the M. D. Anderson Symptom Inventory-Spine Tumor Module. , 2010, Journal of neurosurgery. Spine.

[35]  J. Griggs,et al.  Racial/ethnic differences in job loss for women with breast cancer , 2008, Journal of cancer survivorship : research and practice.

[36]  U. S. Department of Health and Human Services FDA Cen Research,et al.  Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance , 2006, Health and quality of life outcomes.

[37]  M. Gilbert,et al.  Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) , 2006, Journal of Neuro-Oncology.

[38]  C. Bradley,et al.  Correlates of return to work for breast cancer survivors. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Stephen Joel Coons,et al.  US Valuation of the EQ-5D Health States: Development and Testing of the D1 Valuation Model , 2005, Medical care.

[40]  E. Pukkala,et al.  The impact of education and occupation on the employment status of cancer survivors. , 2004, European journal of cancer.

[41]  Jeffrey A. Johnson,et al.  Valuation of EuroQOL (EQ-5D) Health States in an Adult US Sample , 1998, PharmacoEconomics.

[42]  J. Raizer,et al.  Economics of Malignant Gliomas: A Critical Review. , 2015, Journal of oncology practice.

[43]  M. Gilbert,et al.  Symptoms and socio-economic impact of ependymoma on adult patients: results of the Adult Ependymoma Outcomes Project 2 , 2014, Journal of Neuro-Oncology.

[44]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[45]  M. Frings-Dresen,et al.  Interventions to enhance return-to-work for cancer patients. , 2011, The Cochrane database of systematic reviews.

[46]  D. Cella,et al.  Minimally important differences were estimated for six PROMIS-Cancer scales in advanced-stage cancer patients , 2011 .

[47]  C. Varricchio,et al.  NIH State-of-the-Science Statement on symptom management in cancer: pain, depression, and fatigue. , 2002, NIH consensus and state-of-the-science statements.

[48]  Steven Piantadosi,et al.  The prevalence of psychological distress by cancer site , 2001, Psycho-oncology.

[49]  D. Karnofsky The clinical evaluation of chemotherapeutic agents in cancer , 1949 .